Morgan Stanley’s Akero Therapeutics AKRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$37M Sell
693,256
-109,598
-14% -$5.85M ﹤0.01% 2196
2025
Q1
$32.5M Buy
802,854
+331,319
+70% +$13.4M ﹤0.01% 2205
2024
Q4
$13.1M Buy
471,535
+23,465
+5% +$653K ﹤0.01% 3150
2024
Q3
$12.9M Sell
448,070
-498,458
-53% -$14.3M ﹤0.01% 3228
2024
Q2
$22.2M Buy
946,528
+542,665
+134% +$12.7M ﹤0.01% 2546
2024
Q1
$10.2M Sell
403,863
-1,710,791
-81% -$43.2M ﹤0.01% 3333
2023
Q4
$49.4M Buy
2,114,654
+1,674,918
+381% +$39.1M ﹤0.01% 2470
2023
Q3
$22.2M Buy
439,736
+54,078
+14% +$2.74M ﹤0.01% 2336
2023
Q2
$18M Buy
385,658
+28,065
+8% +$1.31M ﹤0.01% 2585
2023
Q1
$13.7M Buy
357,593
+150,593
+73% +$5.76M ﹤0.01% 2845
2022
Q4
$11.3M Buy
207,000
+13,747
+7% +$753K ﹤0.01% 2951
2022
Q3
$6.58M Buy
193,253
+54,050
+39% +$1.84M ﹤0.01% 3423
2022
Q2
$1.32M Sell
139,203
-27,848
-17% -$264K ﹤0.01% 4833
2022
Q1
$2.37M Buy
167,051
+97,627
+141% +$1.39M ﹤0.01% 4386
2021
Q4
$1.47M Buy
69,424
+12,175
+21% +$257K ﹤0.01% 4809
2021
Q3
$1.28M Sell
57,249
-32,354
-36% -$723K ﹤0.01% 4890
2021
Q2
$2.22M Buy
89,603
+59,413
+197% +$1.47M ﹤0.01% 4543
2021
Q1
$876K Buy
30,190
+1,404
+5% +$40.7K ﹤0.01% 4819
2020
Q4
$743K Buy
28,786
+21,699
+306% +$560K ﹤0.01% 4834
2020
Q3
$219K Sell
7,087
-128,503
-95% -$3.97M ﹤0.01% 5064
2020
Q2
$3.38M Buy
135,590
+134,315
+10,535% +$3.35M ﹤0.01% 3070
2020
Q1
$27K Sell
1,275
-5,390
-81% -$114K ﹤0.01% 5702
2019
Q4
$148K Buy
6,665
+5,003
+301% +$111K ﹤0.01% 5521
2019
Q3
$38K Buy
1,662
+1,562
+1,562% +$35.7K ﹤0.01% 5820
2019
Q2
$2K Buy
+100
New +$2K ﹤0.01% 6448